mRNA Vaccines and RNAi Therapeutics Market to Reach $12.31 Billion, Globally, by 2031 at 31.3% CAGR: Allied Market Research

News provided by

Aug 24, 2022, 05:30 ET

Increase in prevalence of chronic & infectious diseases, initiatives taken by governments for large scale sequencing projects, and surge in awareness about vaccination drive the growth of the global mRNA vaccines and RNAi therapeutics market.

PORTLAND, Ore., Aug. 24, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, 'mRNAVaccines and RNAi Therapeutics Market by Disease Type (Hereditary transthyretin-mediated amyloidosis genetic, Acute hepatic porphyria, Primary hyperoxaluria type 1, Atherosclerotic cardiovascular disease), by Route of administration (IV infusion, Subcutaneous), by End user (Research Institutes, Hospitals and clinics): Global Opportunity Analysis and Industry Forecast, 2022-2031.' According to the report, the global mRNA vaccines and RNAi therapeutics industry generated $707.97 million in 2021, and is anticipated to generate $12.31 billion by 2031, witnessing a CAGR of 31.3% from 2022 to 2031.

Download Report (245 Pages PDF with Insights, Charts, Tables, Figures): https://www.alliedmarketresearch.com/request-sample/17623

Prime determinants of growth

Increase in prevalence of chronic & infectious diseases, initiatives taken by governments across the globe for large scale sequencing projects, target specialty & selectivity of treatments, and surge in awareness about vaccination drive the growth of the global mRNA vaccines and RNAi therapeutics market. However, high cost of research, threat of failure, and challenges in quantification of mRNA are anticipated to restrict the market growth. Moreover, application of mRNA technology and development of mRNA biomarker is expected to present new opportunities in the coming years.

Covid-19 Scenario

The outbreak of the Covid-19 pandemic had a positive impact on the global mRNA vaccines and RNAi therapeutics market. mRNA vaccines are promising next-generation vaccines that have introduced a new age in vaccinology.
The recent approval of two COVID-19 mRNA vaccines (mRNA-1273 and BNT162b2) has accelerated mRNA vaccine technology and boosted the pharmaceutical and biotechnology industry.
Human trials with data both from mRNA cancer vaccines and mRNA infectious disease vaccines have provided encouraging results, inspiring the pharmaceutical and biotechnology industries to focus on this area of research.
Furthermore, in mRNA vaccines market, mRNA-based COVID-19 vaccines are a more promising choice compared to conventional vaccine strategies as mRNA vaccine candidates have the capacity for rapid development with high effectiveness.

Scope of the Report: -

Report Attribute	Details
Revenue forecast in 2031	$ 12.31 billion
Growth rate	CAGR of 31.3% from 2022 to 2031
Forecast period	2022 – 2031
Regional scope	North America, Europe, Asia Pacific, Latin America, MEA
Key companies profiled	Alnylam Pharmaceuticals, BioNTech AG, Curevac AG, Etherna Immunotherapies, Ethris GMBH, IN-CELL-ART, Moderna Therapeutics, Sangamo Therapeutics, Inc., Sanofi AG, SCM Life Sciences (Argos Therapeutics, Inc. ), Sarepta Therapeutics, Arcturus Therapeutics, Ionis Pharmaceuticals, Inc, Nutcracker, Tiba Biotech

Specific Requirement on COVID-19? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/request-for-customization/17623?reqfor=covid

The Hereditary transthyretin-mediated amyloidosis genetic segment to maintain its leadership status throughout the forecast period

Based on disease type, the hereditary transthyretin-mediated amyloidosis genetic segment held the highest market share in 2021, accounting for nearly three-fourths of the global mRNA vaccines and RNAi therapeutics market, and is estimated to maintain its leadership status throughout the forecast period, owing to the rise in demand for the treatment of ATTR amyloidosis and the increasing need for the treatment of fatal diseases. However, the atherosclerotic cardiovascular disease segment is projected to manifest the highest CAGR of 33.2% from 2022 to 2031, owing to the high consumption of cholesterol-lowering drugs by patients to reduce blockages in arteries.

The IV infusion segment to maintain its lead position during the forecast period

Based on route of administration, the IV infusion segment accounted for the largest share in 2021, contributing to around two-thirds of the global mRNA vaccines and RNAi therapeutics market, and is projected to maintain its lead position during the forecast period. This is owing to increase in adoption of IV infusion for administration of vaccines and therapeutics. Moreover, the subcutaneous segment is expected to portray the largest CAGR of 31.9% from 2022 to 2031, owing to the cost effectiveness of subcutaneous route of administration as compared to IV infusion.

The hospitals and clinics segment to maintain its lead position during the forecast period

Based on end user, the hospitals and clinics segment accounted for the largest share in 2021, contributing to more than half of the global mRNA vaccines and RNAi therapeutics market, and is projected to maintain its lead position during the forecast period. Moreover, the same segment is expected to portray the largest CAGR of 31.6% from 2022 to 2031, owing to an increase in number of patients with respiratory diseases, cancer and infectious diseases globally.

Purchase Inquiry:
https://www.alliedmarketresearch.com/purchase-enquiry/17623

North America to maintain its dominance by 2031

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than two-fifths of the global mRNA vaccines and RNAi therapeutics market and is expected to lead the trail during the forecast period, owing to a rise in well-established healthcare systems, an increase in number of geriatric patients and supportive reimbursement policies in healthcare system. Moreover, the Asia-Pacific region is expected to witness the fastest CAGR of 33.9% from 2022 to 2031, owing tothe increase in prevalence of chronic diseases and rise in need for mRNA vaccines and RNAi therapeutics for the treatment of such diseases.

Leading Market Players: -

Alnylam Pharmaceuticals
BioNTech AG
Curevac AG
Etherna Immunotherapies
Ethris GMBH
IN-CELL-ART
Moderna Therapeutics
Sangamo Therapeutics, Inc.
Sanofi AG
SCM Life Sciences (Argos Therapeutics, Inc.
Sarepta Therapeutics
Arcturus Therapeutics
Ionis Pharmaceuticals, Inc
Nutcracker
Tiba Biotech

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starte

"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."

Trending Reports in Healthcare Industry (Book Now with 10% Discount + Covid-19 scenario):

Single-use Bioprocessing Market by Product (Bioreactors, Tangential-Flow Filtration Devices, Depth Filters, Disposable Filter Cartridges, Media Bags And Containers, Mixing Systems, Tubing Assemblies, Sampling Systems, Others), by Application (Monoclonal Antibody Production, Vaccine Production, Plant Cell Cultivation, Patient Specific Cell Therapies, Others), by Method (Filtration, Storage, Cell Culture, Mixing, Purification), by End User (Biopharmaceutical Manufacturers, Life Science R&D Companies & Academic Research, Contract Research Organization & Manufacturers): Global Opportunity Analysis and Industry Forecast, 2020-2030

Radiotherapy Market by Type (External Beam Radiation Therapy, Internal Radiation Therapy, Systemic Radiation Therapy), by End User (Hospitals and Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Precision Medicine Market by Technology (Genomics, Transcriptomics and Epigenomics), by Sequencing Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing, Chain Termination Sequencing and Nanopore Sequencing), Product (Consumables, Instruments and Services) Application (Oncology, CNS, Immunology, Respiratory Medicine, Infections, and Other Applications) End User (Diagnostic Tool companies, Pharma & Biotech Companies, Clinical Laboratories, and Healthcare IT/Big Data Companies) - Global Opportunity Analysis and Industry Forecast, 2020-2030

Medical Laser Market by Product Type (Solid-State Laser Systems, Gas Laser Systems, Dye Lasers Systems, and Diode Laser Systems), Application (Ophthalmology, Dermatology, Gynecology, Dentistry, Urology, Cardiovascular, and Others), and End User (Surgical, Cosmetic, and Dental): Global Opportunity Analysis and Industry Forecast, 2020-2030

Women's Health Diagnostics Market By Type (Diagnostic Devices, Diagnostic Tests, Accessories and Consumables), By End User (Hospitals and Clinics, Diagnostic and Imaging Centers, Homecare, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): 1-800-792-5285, 1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
Web: https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow Us on LinkedIn: https://www.linkedin.com/showcase/life-sciences-industry-research/